IDH1 and cholangiocarcinoma: A multicentric phase III trial (ClarIDHy) investigated the role of Ivosidenib, a small-molecule inhibitor of mutated IDH1, in cholangiocarcinoma with IDH1-mutant and refractory to chemotherapy.